Chemotherapy Induced Peripheral Neuropathy Treatment Pipeline Analysis 2025

DelveInsight's "Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis 2025" delivers extensive intelligence on over 4 pharmaceutical firms and more than 5 investigational medications within the Chemotherapy Induced Peripheral Neuropathy development arena. The analysis encompasses profiles of Chemotherapy Induced Peripheral Neuropathy therapeutic candidates, spanning both clinical and preclinical phases. Additionally, it includes evaluation of Chemotherapy Induced Peripheral Neuropathy pipeline therapeutics by product category, developmental phase, administration method, and molecular classification. The report also spotlights dormant development programs in this therapeutic area.

Interested in recent developments within the Chemotherapy Induced Peripheral Neuropathy Pipeline? Discover the emerging treatments and clinical studies generating attention @ Chemotherapy Induced Peripheral Neuropathy Pipeline Outlook Report 

Primary Highlights from the Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis

• On November 5, 2025, Eli Lilly and Company initiated an investigation to evaluate the safety profile and efficacy of a treatment compared to placebo for individuals with nerve pain that originates in their feet and progresses up the leg to just below the knee. Participation may extend up to 30 weeks including screening.

• DelveInsight's Chemotherapy Induced Peripheral Neuropathy Pipeline analysis reveals a dynamic field featuring more than 4 engaged entities advancing over 5 investigational treatments for Chemotherapy Induced Peripheral Neuropathy management.

• Major Chemotherapy Induced Peripheral Neuropathy pharmaceutical firms include Grunenthal GmbH, AlgoTherapeutix, Wex Pharmaceuticals Inc., among additional organizations.

• Notable Chemotherapy Induced Peripheral Neuropathy investigational medications include WST-057, ATX01 10%, Capsaicin, Duloxetine, Olesoxime (TRO19622), ONO-2910, GM1, VMD-3866 Gel, among others.

Curious about which pharmaceutical companies are pioneering advancement in Chemotherapy Induced Peripheral Neuropathy treatment? Explore comprehensive pipeline intelligence @ Chemotherapy Induced Peripheral Neuropathy Clinical Trials Assessment

The Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis delivers a condition synopsis, pipeline landscape, and therapeutic evaluation of principal investigational therapies within this domain. The analysis also emphasizes unaddressed medical requirements concerning Chemotherapy Induced Peripheral Neuropathy.

Chemotherapy Induced Peripheral Neuropathy Background

Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and complex adverse effect of cancer treatment, particularly with common chemotherapy medications. It can emerge during treatment, resulting in dose reductions or early discontinuation, potentially impacting treatment effectiveness and survival outcomes. While acute CIPN often resolves following chemotherapy, in certain cases, it can persist or emerge later, causing long-term manifestations. The prevalence of CIPN remains elevated for months following treatment, varying with the type of chemotherapy utilized and patient-specific factors. Despite improvements in cancer survival rates, CIPN remains a significant challenge for both patients and healthcare providers. The impact on patients' quality of life can be profound, as symptoms like pain, tingling, and numbness affect daily functioning. Moreover, the lack of effective treatments for CIPN further complicates management, making prevention and early intervention critical.

Chemotherapy Induced Peripheral Neuropathy Investigational Drug Profiles

Capsaicin: Grunenthal GmbH

Capsaicin (QUTENZA) is a specially formulated topical system that delivers prescription-strength capsaicin directly to the skin during an in-office procedure. This approach enables it to reversibly desensitize and defunctionalize the TRPV1 (Transient Receptor Potential Vanilloid 1) receptor, which plays a critical role in pain signaling. QUTENZA administered as a single localized procedure can provide sustained pain relief that extends for up to three months. It has no known drug-drug interactions. The most common adverse reactions include application site reactions, such as erythema, pain, and pruritus. Presently, the medication is undergoing Phase III developmental assessment for managing Chemotherapy Induced Peripheral Neuropathy (CIPN).

ATX01: AlgoTherapeutix

ATX01 targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channels. It has been engineered to provide targeted relief from excruciating pain in the feet and hands of patients suffering from Chemotherapy-Induced Peripheral Neuropathy (CIPN). ATX01 has wide potential applicability beyond CIPN, in other conditions where peripheral neuropathic pain is a major issue. By applying the ATX01 hydrogel to the skin, the active ingredient is locally delivered to the nerve endings where pain signals originate and propagate alongside the neurons to the central nervous system. This method of application is especially relevant to CIPN which involves localized pain. Topical administration also minimizes systemic toxicity and drug interactions through limited systemic exposure, which is particularly important in patients exposed to chemotherapy. Presently, the medication is undergoing Phase II developmental assessment for managing Chemotherapy Induced Peripheral Neuropathy (CIPN).

Monitoring active Chemotherapy Induced Peripheral Neuropathy Clinical investigations? This announcement is essential reading. Access the latest advances @ Chemotherapy Induced Peripheral Neuropathy Treatment Drugs

The Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis Offers Intelligence On:

• The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Chemotherapy Induced Peripheral Neuropathy management, including cumulative therapies created by each organization for this indication.

• It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Chemotherapy Induced Peripheral Neuropathy Treatment.

• Chemotherapy Induced Peripheral Neuropathy pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.

• Chemotherapy Induced Peripheral Neuropathy investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.

• Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Chemotherapy Induced Peripheral Neuropathy market.

Chemotherapy Induced Peripheral Neuropathy Pharmaceutical Firms

Grunenthal GmbH, AlgoTherapeutix, Wex Pharmaceuticals Inc., among additional organizations.

The Chemotherapy Induced Peripheral Neuropathy pipeline analysis presents therapeutic evaluation of investigational medications by Administration Method. Products are classified under multiple administration routes including:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Chemotherapy Induced Peripheral Neuropathy products are classified under various molecular categories including:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

From investigational drug candidates to competitive intelligence, the Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis encompasses comprehensive insights - review it today @ Chemotherapy Induced Peripheral Neuropathy Market Drivers and Barriers, and Future Perspectives

Scope of the Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis

• Coverage: Global

• Chemotherapy Induced Peripheral Neuropathy Pharmaceutical Firms: Grunenthal GmbH, AlgoTherapeutix, Wex Pharmaceuticals Inc., among additional organizations.

• Chemotherapy Induced Peripheral Neuropathy Investigational Treatments: WST-057, ATX01 10%, Capsaicin, Duloxetine, Olesoxime (TRO19622), ONO-2910, GM1, VMD-3866 Gel, among others.

• Chemotherapy Induced Peripheral Neuropathy Therapeutic Evaluation by Product Category: Monotherapy, Combination, Mono/Combination

• Chemotherapy Induced Peripheral Neuropathy Therapeutic Evaluation by Clinical Phases: Discovery, Preclinical, Phase I, Phase II, Phase III

Stay informed in Healthcare Research - uncover future directions for the Chemotherapy Induced Peripheral Neuropathy Treatment landscape through this comprehensive analysis @ Chemotherapy Induced Peripheral Neuropathy Emerging Drugs and Major Players

Table of Contents

* Introduction

* Executive Summary

* Chemotherapy Induced Peripheral Neuropathy (CIPN): Overview

* Pipeline Therapeutics

* Therapeutic Assessment

* Chemotherapy Induced Peripheral Neuropathy (CIPN)- DelveInsight's Analytical Perspective

* Late Stage Products (Phase III)

* Capsaicin: Grunenthal GmbH

* Mid Stage Products (Phase II)

* ATX01: AlgoTherapeutix

* Early Stage Products (Phase I)

* Drug Name: Company Name

* Preclinical and Discovery Stage Products

* Drug Name: Company Name

* Inactive Products

* Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Companies

* Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Products

* Chemotherapy Induced Peripheral Neuropathy (CIPN)- Unmet Needs

* Chemotherapy Induced Peripheral Neuropathy (CIPN)- Market Drivers and Barriers

* Chemotherapy Induced Peripheral Neuropathy (CIPN)- Future Perspectives and Conclusion

* Chemotherapy Induced Peripheral Neuropathy (CIPN) Analyst Views

* Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Companies

* Appendix

About Us

DelveInsight is a premier healthcare-oriented market research and advisory organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and comprehensive knowledge of the life sciences and healthcare industries, we provide tailored research solutions and strategic insights to clients worldwide. Partner with us to obtain superior-quality, precise, and current intelligence to maintain competitive advantage.

Contact Us

Kanishk

kkumar@delveinsight.com